ADVERTISEMENT
ADVERTISEMENT
US pharma bets on resilient supply chains
Executives said the rise of contract development and manufacturing organisations (CDMOs) is accelerating change in the sector.
-
1759953093.png)
Staff Reporter - Thu, 30, Apr 2026
- 16:21 EDT
- 17
Representative Image / Logo
Boston, April 30: U.S. leadership in biopharmaceutical manufacturing is being reshaped by rapid technological change, geopolitical uncertainty and the growing need for resilient global supply chains, pharma leaders said.
Executives from major drugmakers said the traditional model of large, centralised manufacturing networks is giving way to more flexible, diversified systems built around speed, advanced therapies and global partnerships.
This post is for paying subscribers only
SUBSCRIBE NOW
ADVERTISEMENT
ADVERTISEMENT
E Paper
Video
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login